LobbyingAmerican Gastroenterological Association lobbying by quarter
American Gastroenterological Association's latest lobbying report covers Q2 2026, at $130K. The four quarters Q3 2025–Q2 2026 total $520K. Its first report covers Q4 2021; the issues it reports most are Health Issues and Medical/Disease Research/Clinical Labs.
American Gastroenterological Association
- Latest quarter
- $130K
- Q2 2026 · 2 reports
- Last 12 months
- $520K
- Last 4 quarters
- vs last quarter
- 0.0%
- Q2 2026 against the quarter before
- First report
- Q4 2021
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q4 2021 | $80K | 1 |
| Q1 2022 | $0 | 0 |
| Q2 2022 | $0 | 0 |
| Q3 2022 | $0 | 0 |
| Q4 2022 | $130K | 2 |
| Q1 2023 | $130K | 2 |
| Q2 2023 | $130K | 2 |
| Q3 2023 | $130K | 2 |
| Q4 2023 | $130K | 2 |
| Q1 2024 | $130K | 2 |
| Q2 2024 | $130K | 2 |
| Q3 2024 | $130K | 2 |
| Q4 2024 | $130K | 2 |
| Q1 2025 | $130K | 2 |
| Q2 2025 | $130K | 2 |
| Q3 2025 | $130K | 2 |
| Q4 2025 | $130K | 2 |
| Q1 2026 | $130K | 2 |
| Q2 2026 | $130K | 2 |
Policy issues the reports name
- Health issues31 reports
- Medical research and clinical labs16 reports
- Medicare and Medicaid16 reports
A report that names several issues counts once for each.
Who was lobbied
- HOUSE OF REPRESENTATIVES31 reports
- SENATE31 reports
Firms it paid
| Firm | ||
|---|---|---|
| In-houseAmerican Gastroenterological Association | $1.3M | 16 quarters |
| Hart Health Strategies | $750K | 15 quarters |
Former officials lobbying for it
| Former position | ||
|---|---|---|
| SUSAN RAMTHUN | Senator Bill Frist | Q2 2026 |
| TIMOTHY YEHL | Congressman Frank Pallone; Senator Frank Lautenberg | Q2 2026 |
| VICKI HART | Senator Bob Dole; Senator Trent Lott | Q2 2026 |
Lobbying reports
| Filed by | ||
|---|---|---|
| 08/17for Q2 | In-house | $80K |
| 07/20for Q2 | Hart Health Strategies | $50K |
| 04/20for Q1 | Hart Health Strategies | $50K |
| 04/08for Q1 | In-house | $80K |
| 02/11for Q4 2025 | In-house | $80K |
| 01/16for Q4 2025 | Hart Health Strategies | $50K |
| 25/11/06for Q3 2025 | In-house | $80K |
| 25/10/20for Q3 2025 | Hart Health Strategies | $50K |
| 25/09/03for Q1 2025 | In-house | $80K |
| 25/08/08for Q2 2025 | In-house | $80K |
| 25/07/10for Q2 2025 | Hart Health Strategies | $50K |
| 25/04/18for Q1 2025 | Hart Health Strategies | $50K |
| 25/02/04for Q4 2024 | In-house | $80K |
| 25/01/05for Q4 2024 | Hart Health Strategies | $50K |
| 24/11/05for Q3 2024 | In-house | $80K |
| 24/10/10for Q3 2024 | Hart Health Strategies | $50K |
| 24/10/10for Q3 2024 | Hart Health Strategies | $50K |
| 24/08/23for Q2 2024 | In-house | $80K |
| 24/07/21for Q2 2024 | Hart Health Strategies | $50K |
| 24/05/07for Q1 2024 | In-house | $80K |